India Hepatitis Elimination Pledge at UNGA 81
Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The reaffirmed hepatitis elimination commitment and the CDSCO advisory on NSAIDs and antibiotics signal continued tightening of India's pharmaceutical regulation, which could modestly affect sales volumes for over-the-counter painkiller and antibiotic makers while supporting demand for diagnostics, antivirals and hepatitis screening programs. Overall market impact is limited and largely confined to Indian pharma and healthcare names, with no broad macroeconomic or cross-asset implications.
At a side event of the 81st session of the International — United Nations General Assembly titled Advancing Global Action to Eliminate Hepatitis, organized by the UN Group of Friends to Eliminate Hepatitis, Union Health Secretary Punya Salila Srivastava reaffirmed India's commitment to the 2030 Sustainable Development Goals agenda on combating Hepatitis and to the global target of eliminating Hepatitis B and C as public health threats by 2030. According to the Bangladesh — Ministry of Health and Family Welfare, India's approach is people-centred and spans prevention, screening, diagnosis, treatment and care, aimed at reducing the disease burden through early detection and treatment. In a separate development, the India — Central Drugs Standard Control Organisation issued an advisory circular, dated September 21, to healthcare professionals, pharmacists, retailers, distributors, hospitals and the general public warning against the indiscriminate use of painkillers, particularly Non-Steroidal Anti-Inflammatory Drugs, and antibiotics, citing associated risks of Chronic Kidney Disease. According to the India — Directorate General of Health Services, such drugs should only be used when clinically indicated, in appropriate doses and for the recommended duration, under the supervision of a Registered Medical Practitioner. The circular noted that most NSAIDs fall under Schedule H of the Drugs Rules, 1945 and cannot be sold at retail without prescription, while most antibiotics fall under Schedule H1 and must carry specific warnings, with import, manufacturing, sale and distribution regulated under the Drugs and Cosmetics Act, 1940.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard